OTC Markets OTCPK - Delayed Quote USD

Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

Compare
4.1400 +4.1400 (0.00%)
As of November 15 at 3:00 PM EST. Market Open.
Loading Chart for HNGZY
DELL
  • Previous Close 4.1400
  • Open 4.1400
  • Bid 2.0500 x --
  • Ask 29.4500 x --
  • Day's Range 4.1400 - 4.1400
  • 52 Week Range 4.1400 - 7.7800
  • Volume 1,200
  • Avg. Volume 25
  • Market Cap (intraday) 6.942B
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) 27.60
  • EPS (TTM) 0.1500
  • Earnings Date Oct 29, 2024
  • Forward Dividend & Yield 0.08 (1.93%)
  • Ex-Dividend Date Jun 11, 2024
  • 1y Target Est --

Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

www.tigermedgrp.com

9,701

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HNGZY

View More

Performance Overview: HNGZY

Trailing total returns as of 11/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HNGZY
0.48%
SSE Composite Index
11.73%

1-Year Return

HNGZY
45.76%
SSE Composite Index
8.82%

3-Year Return

HNGZY
67.53%
SSE Composite Index
0.31%

5-Year Return

HNGZY
67.53%
SSE Composite Index
0.31%

Compare To: HNGZY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HNGZY

View More

Valuation Measures

Annual
As of 11/15/2024
  • Market Cap

    6.94B

  • Enterprise Value

    7.23B

  • Trailing P/E

    26.97

  • Forward P/E

    17.09

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.81

  • Price/Book (mrq)

    1.23

  • Enterprise Value/Revenue

    7.69

  • Enterprise Value/EBITDA

    22.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.10%

  • Return on Assets (ttm)

    2.77%

  • Return on Equity (ttm)

    4.19%

  • Revenue (ttm)

    6.8B

  • Net Income Avi to Common (ttm)

    958.67M

  • Diluted EPS (ttm)

    0.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.04B

  • Total Debt/Equity (mrq)

    17.00%

  • Levered Free Cash Flow (ttm)

    -10.74M

Research Analysis: HNGZY

View More

Company Insights: HNGZY

Research Reports: HNGZY

View More

People Also Watch